Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy. Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Question

Want to see the full answer?

Answer 1

Question

Chapter ST.6, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Students have asked these similar questions

Describe how insulin binding to its receptor induces glucose uptake in healthy individuals. Please specifyeach step in the cascade and use a diagram to illustrate the answer.

There is a patient with breast cancer, after staining the breast tissue with H&E, state the molecular subtype of the tumour extracted. Results of H&E staining are down below

Biopharmaceutics and Pharmacokinetics:Two-Compartment Model Instant Absorption Questions Calculate these : a) B1, b) B2, c) hybrid rate constant (1) d) hybrid rate constant (2) e) t1/2,dist f) t1/2,elim g) k10 h) k12 i) k21 j) initial concentration (C0) k) central compartment volume (V1) l) steady-state volume (Vss) m) clearance (CL) AUC (0→10 min) using trapezoidal rule n) AUC (20→30 min) using trapezoidal rule o) AUCtail (AUC360→∞) p) total AUC (using short cut method) q) volume from AUC (VAUC)

Answer 2

Question

Chapter ST.6, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 3

Question

Chapter ST.6, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 4

Question

Chapter ST.6, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 5

Chapter ST.6, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Answer 6

Chapter ST.6, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Answer 7

Chapter ST.6, Problem 6RQ

Summary Introduction

To determine: Whether the therapeutic gene delivered to Ashanti replaced the defective copy of the ADA gene at the time of the first successful trial of gene therapy.

Introduction: The FDA approved the first human gene therapy trial in 1990. This therapy started with the treatment of a young girl named Ashanti De Silva. She has a heritable disorder called adenosine deaminase severe combined immunodeficiency (ADA-SCID). SCID is a hereditary disease that is a result of many genetic mutations, such as the abnormal development of B and T cells.

Answer 8

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Answer 9

Summary Introduction

To determine: The reason for choosing white blood cells as the targets for the therapeutic gene.

Introduction: ADA-SCID is a condition that is affecting nearly 1-9 out of every 1 million live births. Individuals suffering from SCID lack a normal immune system. They generally die from minor infections.

Answer 10

Expert Solution & Answer

Answer 11

Expert Solution & Answer

Answer 12

Want to see the full answer?

Check out a sample textbook solution

See solution

Answer 13

Ch. ST.1 - Prob. 1RQ Ch. ST.1 - Prob. 2RQ Ch. ST.1 - Prob. 3RQ Ch. ST.1 - Prob. 4RQ Ch. ST.1 - Prob. 5RQ Ch. ST.1 - Prob. 6RQ Ch. ST.1 - Prob. 7RQ Ch. ST.1 - How do microRNAs regulate epigenetic mechanisms...Ch. ST.1 - Prob. 9RQ Ch. ST.1 - Imprinting disorders do not involve changes in...

Solution Summary: The author explains that the therapeutic gene delivered to Ashanti did not replace the defective copy of the ADA gene.

Concept explainers

Videos

Want to see the full answer?

Chapter ST Solutions